Central lead administration inhibits water intake and sodium appetite in rats.
We have demonstrated that acute third ventricle injections of lead acetate (PbAc) exert a powerful antidipsogenic effect and induce a significant increase in renal sodium excretion. In the present study we confirm the antidipsogenic effect of lead and demonstrate that central administration of this metal, in minute amounts, significantly reduces salt intake both during dehydration and after central angiotensinergic stimulation. Adult male Wistar rats had the third ventricle cannulated seven days before the experiments. During this period they had free access to distilled water and hypertonic saline solution (1.5%). After a 24-h period of fluid deprivation, experimental animals received third ventricle injections of PbAc (0.3, N = 8 and 3.0 nmol/rat, N = 14) while controls received sodium acetate (NaAc; 3.0 nmol/rat, N = 10). Rats treated with PbAc at the highest dose showed a significant reduction (P<0.05) both in water and hypertonic saline intake when compared to controls. When the effect of lead administration on angiotensin II-induced water and salt intake was studied, normohydrated animals received third ventricle injections of angiotensin II (9.6 nmol/rat) after pretreatment with 3.0 nmol/rat of PbAc (experimental group, N = 10) or NaAc (controls, N = 8). The group pretreated with PbAc presented a significant reduction (P<0.05) in both water and salt intake compared to controls. Thus, this study confirms the antidipsogenic effect of central lead injections and demonstrates that the presence of lead in the brain exerts a significant inhibition of sodium appetite.
De-Castro-e-Silva
E J
EJ
Departamento de Fisiologia, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, BA, Brasil. emilio@svn.com.br
Castro
L
L
Luz
C P
CP
Ferreira
H
H
Lima
A K
AK
Souza
F S
FS
Maldonado
I
I
Macêdo
D F
DF
Ferreira
M G
MG
Bandeira
I P
IP
Amor
A L
AL
Carvalho
F L
FL
Rocha
M A
MA
Fregoneze
J B
JB
D000809:Angiotensins / Q000494:pharmacology*; D000818:Animals; D001066:Appetite / Q000187:drug effects*; D001826:Body Fluids / Q000187:drug effects; D004326:Drinking / Q000187:drug effects*; D007276:Injections, Intraventricular; D008297:Male; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012982:Sodium, Dietary / Q000008:administration & dosage*
D000809:Angiotensins; D009942:Organometallic Compounds; D012982:Sodium, Dietary; C008261:lead acetate